Juan C. Jaen - 05 Jan 2026 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Role
President
Signature
/s/ Carolyn Tang, Attorney-in-Fact
Issuer symbol
RCUS
Transactions as of
05 Jan 2026
Net transactions value
-$681,342
Form type
4
Filing time
07 Jan 2026, 16:15:35 UTC
Previous filing
18 Dec 2025
Next filing
26 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Jaen Juan C. President C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY, HAYWARD /s/ Carolyn Tang, Attorney-in-Fact 07 Jan 2026 0001422996

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCUS Common Stock Sale $633,158 -29,670 -3.1% $21.34 924,393 05 Jan 2026 By Trust F1, F2
transaction RCUS Common Stock Sale $45,864 -2,053 -0.22% $22.34 922,340 05 Jan 2026 By Trust F1, F3
transaction RCUS Common Stock Sale $2,320 -100 -0.01% $23.20 922,240 05 Jan 2026 By Trust F1
holding RCUS Common Stock 346,012 05 Jan 2026 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2025.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.975 to $21.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.04 to $22.985, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 Includes the unvested portion of the reporting person's RSU grants.